Encapsulation of Ferrocene Methylamine in a Metal–Organic Framework for Enhanced Oxygen Evolution Reaction

2D conductive Metal–organic frameworks (MOFs) have emerged as promising electrocatalysts. Their unique conjugated structure leads to rapid electron transfer rates and confers excellent electrical conductivity. However, the electrocatalysis environments always involve complicated multiphase interactions. The electrocatalytic efficiencies for 2D MOF are often hampered by low electrical conductivity in solvation and improper adsorption/desorption energy of intermediates, which refers to the electron transfer efficiency between the solid catalysts and solution, as well as the solid catalysts and the gas molecules. In this study, we addressed these limitations by encapsulating guest molecules into the hexagonal nanocavity of 2D MOF. Fc-Ni-HHTP was synthesized by introducing ferrocene derivatives (ferrocene methylamine, Fc-NH2) into Ni-HHTP (HHTP = 2,3,6,7,10,11-hexahydroxytriphenylene). It exhibited superior performance in the oxygen evolution reaction (OER) compared to Ni-HHTP, with an overpotential of 482 mV at a current density of 10 mA cm–2, demonstrating excellent electrochemical stability. Density functional theory (DFT) calculations showed that the remarkable electrocatalytic performance of Fc-Ni-HHTP was attributed to the synergistic effect between the ferrocene derivatives and the Ni-HHTP matrix. This work provides a notable way to enhance the electrocatalytic performance of MOFs by introducing a guest molecule into a MOF to improve the multiphase electron transfer rates

Electromagnetic power radiation in (a) lossless and (b) lossy media.

<p>(The solid line represents the FDTD calculated data and dotted line represents the analytical data. The power radiation is normalized and is shown as a function of radial distance from the dipole.).</p

NiMoS₃ Nanorods as pH-Tolerant Electrocatalyst for Efficient Hydrogen Evolution

To meet the increasing demands for sustainable and clean hydrogen energy sources, development of pH-tolerant electrocatalysts with high-performance and low-cost toward hydrogen evolution reaction (HER) is an important but challenging task. MoS₂ is postulated as a promising candidate for HER in acidic solution, however, showing poor activity in alkaline media. Herein, to widen its application in various media, we first report the synthesis of NiMoS₃ nanorods using a hydrothermal method that starts from NiMoO₄ nanorods. The incorporation of Ni atoms in Mo–S could arouse the synergism of ternary Ni–Mo–S and create abundant defect sites, thus substantially improving the inherent catalytic activity and catalytic sites. More importantly, Ni endows Mo–S with excellent catalytic activity in alkaline solution. As a result, NiMoS₃ exhibits large cathodic current, low overpotetnial, and stable durability for HER in H₂SO₄ and especially in KOH. The overpotetnial at current density of 10 mA cm^–2 is as low as 126 mV in KOH, making it a promising candidate for HER electrocatalyst

Logarithmic SAR and temperature (T) distributions for the 3 antennas positioned at 0-mm brain depth.

<p>Logarithmic SAR and temperature (T) distributions for the 3 antennas positioned at 0-mm brain depth.</p

DataSheet_2_Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis.pdf

BackgroundThe objective of this study is to evaluate the efficacy and safety of different third-line treatment regimens for metastatic colorectal cancer (mCRC) through a comprehensive analysis and network meta-analysis (NMA). Additionally, the study aims to provide guidance on selecting appropriate third-line systemic treatment regimens for patients with mCRC.MethodsWe conducted a search of the PubMed, Embase, Web of Science, and Cochrane Central Register of Controlled Trials databases from January 1, 2005, to May 20, 2023, to include phase II/III randomized clinical trials (RCTs) of third-line treatments for mCRC. The primary outcome assessed in the NMA was median overall survival (mOS), and other outcomes included median progression-free survival (mPFS), disease control rate (DCR), and grade 3 or higher adverse events (≥3AEs).ResultsUltimately, nine phase II/III RCTs involving five treatment regimens were included in this study. Trifluridine/tipiracil (TAS-102) plus bevacizumab (hazard ratio [HR] 0.41, 95% credible interval [CrI] 0.32-0.52) was found to be the most effective treatment for mOS compared to best supportive care (BSC). TAS-102 plus bevacizumab also significantly improved mPFS compared to BSC (HR 0.20, 95% CrI 0.16-0.25). In terms of adverse events (AEs), TAS-102 (RR 0.52, 95% CrI 0.35-0.74) had a lower incidence of ≥3AEs compared to fruquintinib, but fruquintinib (RR 1.79, 95% CrI 1.10-3.11) showed better improvement in DCR than TAS-102. Subgroup analysis using the Bayesian surface under the cumulative ranking curve (SUCRA) ranked the regimens based on the OS benefit. The results indicated that TAS-102 plus bevacizumab ranked first across age, gender, Eastern Cooperative Oncology Group performance status (ECOG PS), and time from initial diagnosis of metastatic disease to randomization.ConclusionTAS-102, fruquintinib, TAS-102 plus bevacizumab, the regorafenib standard dose regimen (regorafenib), and the regorafenib dose-escalation regimen (regorafenib 80+) all demonstrated improved OS and PFS compared to BSC in mCRC patients. However, TAS-102 plus bevacizumab may be the optimal choice for third-line treatment in mCRC patients.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php, CRD42023434929.</p

Sagittal view of the human head model.

<p>(Lines represent simulated positions of the transmitting/external antenna outside of the head and the implanted neural interfaces at 4 different depths inside the skull.).</p

Ligand-Free Pd-Catalyzed Domino Synthesis of Carbazoles via Dehydrogenative Aromatization/C(sp²)–C(sp²) Coupling Sequence

A palladium-catalyzed domino reaction via a dehydrogenative aromatization and a dual C­(sp²)–H functionalization process for one-pot synthesis of carbazoles under ligand-free conditions has been developed. On the basis of the catalytic system, carbazoles can be synthesized in moderate to good yields from facile arylamines and cyclic ketones, which presents straightforward and practical C­(sp²)–C­(sp²) bond formation

Janus Nanocage toward Platelet Delivery

The platelet-shaped Janus nanocages with a mesoporous silica shell are prepared. PEG moiety onto the exterior surface is responsible for good dispersity in water. The graphene sheet inside the cavity is responsible for hydrophobic performance to selectively capture hydrophobic species, and photothermal effect by NIR irradiation. As a biocompatible DOX-loaded Janus platelet delivery, HeLa cell cytotoxicity is greatly enhanced under NIR irradiation. There exists a synergetic effect between the chemotherapy and photothermal therapy

DataSheet_1_Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis.docx

BackgroundThe objective of this study is to evaluate the efficacy and safety of different third-line treatment regimens for metastatic colorectal cancer (mCRC) through a comprehensive analysis and network meta-analysis (NMA). Additionally, the study aims to provide guidance on selecting appropriate third-line systemic treatment regimens for patients with mCRC.MethodsWe conducted a search of the PubMed, Embase, Web of Science, and Cochrane Central Register of Controlled Trials databases from January 1, 2005, to May 20, 2023, to include phase II/III randomized clinical trials (RCTs) of third-line treatments for mCRC. The primary outcome assessed in the NMA was median overall survival (mOS), and other outcomes included median progression-free survival (mPFS), disease control rate (DCR), and grade 3 or higher adverse events (≥3AEs).ResultsUltimately, nine phase II/III RCTs involving five treatment regimens were included in this study. Trifluridine/tipiracil (TAS-102) plus bevacizumab (hazard ratio [HR] 0.41, 95% credible interval [CrI] 0.32-0.52) was found to be the most effective treatment for mOS compared to best supportive care (BSC). TAS-102 plus bevacizumab also significantly improved mPFS compared to BSC (HR 0.20, 95% CrI 0.16-0.25). In terms of adverse events (AEs), TAS-102 (RR 0.52, 95% CrI 0.35-0.74) had a lower incidence of ≥3AEs compared to fruquintinib, but fruquintinib (RR 1.79, 95% CrI 1.10-3.11) showed better improvement in DCR than TAS-102. Subgroup analysis using the Bayesian surface under the cumulative ranking curve (SUCRA) ranked the regimens based on the OS benefit. The results indicated that TAS-102 plus bevacizumab ranked first across age, gender, Eastern Cooperative Oncology Group performance status (ECOG PS), and time from initial diagnosis of metastatic disease to randomization.ConclusionTAS-102, fruquintinib, TAS-102 plus bevacizumab, the regorafenib standard dose regimen (regorafenib), and the regorafenib dose-escalation regimen (regorafenib 80+) all demonstrated improved OS and PFS compared to BSC in mCRC patients. However, TAS-102 plus bevacizumab may be the optimal choice for third-line treatment in mCRC patients.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php, CRD42023434929.</p

The differentiated Gaussian pulse in (a) time and (b) frequency domains used to power the implanted antenna.

<p>The differentiated Gaussian pulse in (a) time and (b) frequency domains used to power the implanted antenna.</p